CDKN2A and lymphoma: Using Arf−/−Eμ-Myc/Bcl-2 mouse lymphoma cells, which overexpressed c-MYC and exogenous BCL-2 and were resistant to ABT-737, we found that suppression of DHX9 synergized with ABT-737 to reverse resistance.